Exchange: NASDAQ·Updated 07:37 PM EDT

MDXG News

News
all
press releases
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
The Federal Trade Commission issued a Second Request on Friday, seeking additional documents and information from both companies for the merger.
Stocktwits
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
The Federal Trade Commission issued a Second Request on Friday, seeking additional documents and information from both companies for the merger.
Stocktwits
More News
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts PR Newswire TAMPA, Fla., June 2, 2026 Issued on behalf of Conexeu Sciences Inc.A newly listed...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx...
PR Newswire
Is the Options Market Predicting a Spike in MiMedx Group Stock?
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx...
PR Newswire
MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered MiMedx Group from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat
MiMedx Group (NASDAQ:MDXG) Stock Price Up 7% - Still a Buy?
MiMedx Group (NASDAQ:MDXG) Shares Up 7% - Should You Buy...
MarketBeat
MiMedx Group (NASDAQ:MDXG) Price Target Lowered to $6.00 at Citizens Jmp
Citizens Jmp dropped their price objective on MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating on the stock in a report on Thursday...
MarketBeat
MiMedx Group (NASDAQ:MDXG) Issues Earnings Results
MiMedx Group (NASDAQ:MDXG - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by...
MarketBeat
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +28.57% and +3.49%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.